This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of ThromboGenics in any jurisdiction. No securities of ThromboGenics may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.For further information please contact: Thrombogenics Wouter Piepers, Global Head of Corporate Communications +32 16 75 13 10 / +32 478 33 56 32 Wouter.email@example.com Dr. Patrik De Haes, CEO +32 16 75 13 10 Patrik.firstname.lastname@example.org Chris Buyse, CFO +32 16 75 13 10 Chris.email@example.com Citigate Dewe Rogerson David Dible/ Nina Enegren/ Sita Shah Tel: +44 20 7638 9571 firstname.lastname@example.org The Trout Group (US investor relations) Todd James/ Simon Harnest Tel: +1 646 378 2926 email@example.com
Germany's IQWiG Confirms That ThromboGenics' JETREA® Demonstrates Major Added Value For The Treatment Of Vitreomacular Traction And Macular Hole
Check Out Our Best Services for Investors
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Model portfolio
- Stocks trading below $10
- Intraday trade alerts
More than 30 investing pros with skin in the game give you actionable insight and investment ideas.